JP2020511425A5 - - Google Patents

Download PDF

Info

Publication number
JP2020511425A5
JP2020511425A5 JP2019539809A JP2019539809A JP2020511425A5 JP 2020511425 A5 JP2020511425 A5 JP 2020511425A5 JP 2019539809 A JP2019539809 A JP 2019539809A JP 2019539809 A JP2019539809 A JP 2019539809A JP 2020511425 A5 JP2020511425 A5 JP 2020511425A5
Authority
JP
Japan
Prior art keywords
peptide according
use according
apoc
peptide
hypertriglyceridemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019539809A
Other languages
English (en)
Japanese (ja)
Other versions
JP7353973B2 (ja
JP2020511425A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/014532 external-priority patent/WO2018136803A1/en
Publication of JP2020511425A publication Critical patent/JP2020511425A/ja
Publication of JP2020511425A5 publication Critical patent/JP2020511425A5/ja
Priority to JP2023100171A priority Critical patent/JP2023116739A/ja
Application granted granted Critical
Publication of JP7353973B2 publication Critical patent/JP7353973B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019539809A 2017-01-19 2018-01-19 Apoc-ii模倣ペプチド Active JP7353973B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023100171A JP2023116739A (ja) 2017-01-19 2023-06-19 Apoc-ii模倣ペプチド

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762448358P 2017-01-19 2017-01-19
US62/448,358 2017-01-19
US201762476535P 2017-03-24 2017-03-24
US201762476531P 2017-03-24 2017-03-24
US62/476,535 2017-03-24
US62/476,531 2017-03-24
PCT/US2018/014532 WO2018136803A1 (en) 2017-01-19 2018-01-19 Apoc-ii mimetic peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023100171A Division JP2023116739A (ja) 2017-01-19 2023-06-19 Apoc-ii模倣ペプチド

Publications (3)

Publication Number Publication Date
JP2020511425A JP2020511425A (ja) 2020-04-16
JP2020511425A5 true JP2020511425A5 (cg-RX-API-DMAC7.html) 2021-02-04
JP7353973B2 JP7353973B2 (ja) 2023-10-02

Family

ID=62908746

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019539809A Active JP7353973B2 (ja) 2017-01-19 2018-01-19 Apoc-ii模倣ペプチド
JP2023100171A Pending JP2023116739A (ja) 2017-01-19 2023-06-19 Apoc-ii模倣ペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023100171A Pending JP2023116739A (ja) 2017-01-19 2023-06-19 Apoc-ii模倣ペプチド

Country Status (14)

Country Link
US (2) US11136372B2 (cg-RX-API-DMAC7.html)
EP (1) EP3571216B1 (cg-RX-API-DMAC7.html)
JP (2) JP7353973B2 (cg-RX-API-DMAC7.html)
KR (1) KR102700862B1 (cg-RX-API-DMAC7.html)
CN (1) CN110831957B (cg-RX-API-DMAC7.html)
AU (1) AU2018210404B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019014707A2 (cg-RX-API-DMAC7.html)
CA (1) CA3050106A1 (cg-RX-API-DMAC7.html)
IL (2) IL268093B2 (cg-RX-API-DMAC7.html)
MX (1) MX2019008529A (cg-RX-API-DMAC7.html)
NZ (1) NZ755599A (cg-RX-API-DMAC7.html)
SG (2) SG11201906422VA (cg-RX-API-DMAC7.html)
TW (2) TW202130652A (cg-RX-API-DMAC7.html)
WO (1) WO2018136803A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018210404B2 (en) 2017-01-19 2022-01-27 Novo Nordisk A/S ApoC-II mimetic peptides
US20240309065A1 (en) * 2021-06-23 2024-09-19 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Short apoc-ii mimetic peptides and methods of use
CN119233984A (zh) * 2022-05-05 2024-12-31 美国政府(由卫生和人类服务部的部长所代表) 短载脂蛋白e模拟肽及其使用方法
US20240043499A1 (en) * 2022-08-07 2024-02-08 Protean Bio, Inc. Peptides for beta-cell survival and insulin production

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6156727A (en) * 1996-09-05 2000-12-05 Uab Research Foundation Anti-atherosclerotic peptides and a transgenic mouse model of antherosclerosis
NZ532217A (en) 2001-09-28 2006-12-22 Esperion Therapeutics Inc Use of an alpha helical apolipoprotein or HDL associating protein adapted to be administered locally to prevent or reduce stenosis or restenosis or to stabilize a plaque
US7220576B2 (en) * 2002-01-07 2007-05-22 Lifesensors, Inc. Methods and compositions for protein expression and purification
CA2512879A1 (en) * 2003-01-17 2004-08-12 Soumya P. Sahoo N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
EP1706131A4 (en) * 2003-12-15 2009-08-12 Univ California THE CELLULAR CHOLESTEROL EFFLUX STIMULATING HELICULAR SYNTHETIC PEPTIDES
AU2005214225B2 (en) * 2004-02-19 2010-05-20 Banyu Pharmaceutical Co., Ltd. Novel sulfone amide derivative
JP5048486B2 (ja) * 2004-07-16 2012-10-17 トラスティーズ オブ タフツ カレッジ アポリポタンパク質a1の模倣物とその使用
AU2006263332B2 (en) * 2005-06-29 2012-02-23 Hadasit Medical Research Services & Development Ltd. Protein kinase C inhibitors for prevention of insulin resistance and type 2 diabetes
US20080138284A1 (en) * 2006-09-26 2008-06-12 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
WO2009097584A1 (en) * 2008-01-30 2009-08-06 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
WO2009129263A1 (en) * 2008-04-15 2009-10-22 The Government Of The Usa As Represented By The Secretary Of The Department Of Health & Human Serv. Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase
CN102753576A (zh) * 2009-09-30 2012-10-24 首尔大学教产学协力团 载脂蛋白a-1模拟肽以及包含其的用于治疗高血脂及高血脂相关疾病的治疗剂
US10087234B2 (en) 2012-11-06 2018-10-02 Les Hopitaux Universitaires De Geneve Mimetic peptides
AU2018210404B2 (en) 2017-01-19 2022-01-27 Novo Nordisk A/S ApoC-II mimetic peptides
EA201991491A1 (ru) 2017-03-24 2019-12-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сервисис Миметические пептиды apoc-ii

Similar Documents

Publication Publication Date Title
JP7497381B2 (ja) Fgf21変異体
JP7309606B2 (ja) 活性比が最適化されたfgf21化合物/glp-1rアゴニスト組合せ物
JP6227629B2 (ja) ヒトアミリン類似体
CN103596972B (zh) 多肽
JP5485876B2 (ja) 代謝疾患の治療における治療剤としての非アシル化グレリン
DK2344519T3 (en) C-TERMINAL FRAGMENTS OF GLUCAGON SIMILAR PEPTID-1 (GLP-1)
DK2389388T3 (en) TREATMENT FOR Obesity
JP2021528422A (ja) 最適化された活性比を有するfgf21化合物/glp−1rアゴニストの組合せ
EP3570875B1 (en) Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use
CN106661096A (zh) 新的艾塞那肽类似物及其用途
WO2022177878A1 (en) Glucagon-like peptide-1 receptor antagonists
KR102700862B1 (ko) apoC-II 모방 펩타이드
CN119654159A (zh) 胰高血糖素样肽-1受体拮抗剂
RU2010120571A (ru) Тимус-специфический белок
WO2015180634A1 (zh) 用于治疗2型糖尿病的长效肠激素多肽类似物及应用
CN109195983B (zh) 胰岛新生多肽和类似物的缀合物及其方法
JP2024532882A5 (cg-RX-API-DMAC7.html)
HK40034568A (en) Fgf21 variants
WO2014014816A2 (en) Methods of treating glucose metabolism disorders